Database : HANSEN Search on : HANSENOSTATICOS/ADMIN [Subject descriptor] References found : 64 [refine] Displaying: 1 .. 20   in format [Detailed]

page 1 de 4

go to page

1 / 64

HANSEN

select to print Texto Completo-en

Id: 19878 Author: Ji, Baohong. Title: Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks. Source: Int. J. Lepr;66(3):391-391, Sept. 1998. . Descriptors: Hanseníase/quimioter Hansenostáticos/admin Hansenostáticos/uso terap Limits: Humanos Masculino Feminino Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3cor03.pdf / en Location: BR191.1

2 / 64

HANSEN

select to print

Id: 18385 Author: Consigny, Sophie; Bentoucha, Abdelhalim; Bonnafous, Pascale; Grosset, Jacques; Ji, Baohong Title: Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice ..- Source: s.l; s.n; 2000. 3 p. tab. Abstract: Bactericidal activities of HMR 3647 (HMR), moxifloxacin (MXFX), and rifapentine (RPT) against Mycobacterium leprae, measured by the proportional bactericidal technique in the mouse footpad system, were compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO), and rifampin (RMP. Administered in five daily doses of 100 mg/kg of body weight, HMR appeared slightly more bactericidal than CLARI. In a single dose, MXFX at 150 mg/kg was more active than the same dose of OFLO and displayed exactly the same level of activity as RMP at 10 mg/kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT at 10mg/kg was more bactericidal than the same dose of RMP and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae and was slighthy more bactericidal than RPT alone, indicating that the combination PMM showed an additive effect against M. leprae (AU). Descriptors: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/farmacol HANSENOSTATICOS/farmacocin HANSENOSTATICOS/uso terap MYCOBACTERIUM LEPRAE TESTES DE SENSIBILIDADE MICROBIANA/métodos DROGAS EM INVESTIGACAO/admin DROGAS EM INVESTIGACAO/anal DROGAS EM INVESTIGACAO/uso terap - BACTERICIDAS  QUIMIOTERAPIA COMBINADA  MYCOBACTERIUM LEPRAE/metab  MYCOBACTERIUM LEPRAE/fisiol  DAPSONA/uso terap  RIFAMPINA/uso terap  CLOFAZIMINA/uso terap  OFLOXACINO/uso terap  MINOCICLINA/uso terap  CLARITROMICINA/uso terap Limits: ESTUDO COMPARATIVO Location: BR191.1; 09311/s

3 / 64

HANSEN

select to print

Id: 18384 Author: Biswas, S; Mondal, K. K Title: Multidrug therapy in leprosy can prevent relapse- a retrospective study ..- Source: s.l; s.n; 2002. 6 p. . Abstract: A retrospective study was done at the Leprosy Control Unit (LCU) in Durgapur of Burdwan district, West Bengal, to determine the relapse rate following multidrug therapy (MDT). A total of 1581 patients (1276 PB and 305 MB) completed MDT regimens during a period of 5 years as per WHO recommendations and National Leprosy Eradication Programme (NLEP) guidelines. The treated patients were kept under surveillance as per NLEP guidelines and searched for relapses. The results of MDT were compared with those of pre-MDT (monotherapy) era at the same centre (total: 405 patients; PB-373, MB-32) andalso with those of the Leprosy Clinic in Gopalpur (only dapsone was given to a total of 189 patients, PB-167, MB-22) Following monotherapy, the relapse rate was 10.06% at the Gopalpur Leprosy Clinic and 12.4% at the Dargapur LCU during the 2 years (PB) and 5 years (MB) of surveillance, whereas following MDT no relapse case was encountered both in PB and MB cases during the surveillance periods recommended by WHO. The results of this study are comparable with those of ohter studies. Though a few studies showed relapses during long-term surveillance beyond the periods recommended by WHO, it is once again established that MDT can prevent relapse in leprosy (AU). Descriptors: HANSENIASE/quimioter HANSENIASE/epidemiol HANSENIASE/prev RECIDIVA/prev - HANSENOSTATICOS/admin  HANSENOSTATICOS/hist  HANSENOSTATICOS/normas  HANSENOSTATICOS/uso terap  CLOFAZIMINA/uso terap  DAPSONA/uso terap  RIFAMPINA/uso terap Limits: ESTUDO COMPARATIVO HUMANO Location: BR191.1; 09310/s

4 / 64

HANSEN

select to print

Id: 18281 Author: Hertaing, R. de; Coutejore, J Title: La lepre aujourd'hui: conceptions recentes de la lutte contre la lepre ..- Source: Kangu; s.n; s.d. 40 p. ilus, mapas. Descriptors: HANSENIASE DIMORFA/compl HANSENIASE DIMORFA/diag HANSENIASE VIRCHOWIANA/compl HANSENIASE VIRCHOWIANA/diag HANSENIASE TUBERCULOIDE/compl HANSENIASE TUBERCULOIDE/diag HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag HANSENIASE/hist HANSENIASE/imunol HANSENIASE/microbiol HANSENIASE/prev HANSENIASE/terap HANSENIASE/transm HANSENOSTATICOS/admin HANSENOSTATICOS/uso terap HANSENIASE/epidemiol - EDUCACAO EM SAUDE/rec hum  EDUCACAO EM SAUDE/métodos  EDUCACAO EM SAUDE/org  EDUCACAO EM SAUDE/tend Limits: HUMANO Location: BR191.1; 00456/s

5 / 64

HANSEN

select to print

Id: 18280 Author: Ustianowski, Andrew P; Lockwood, Diana N. J Title: Leprosy: current diagnostic and treatment approaches ..- Source: s.l; s.n; 2003. 7 p. . Abstract: PURPOSE OF REVIEW: Leprosy remains an important problem globally and leprosy patients may present to physicians outside leprosy endemic areas. We review the recent biological and clinical advances in leprosy. RECENT FINDINGS: Sequencing the genome has been a major biological advance and will open up new possibilities for research. The three cardinal criteria (anaesthetic skin patches, thickened nerves and acid-fast bacilli in skin smears) have not yet been bettered. Multidrug therapy for leprosy is highly effective with low relapse rates though the optimal duration of therapy for multibacillary patients is unclear. Nerve damage remains a significant problem (in some series only 50% responding to steroid therapy). New treatments for leprosy reactions are needed. Stigma remains a problem but is being combated by patient groups. SUMMARY: Far from being eliminated as a public health problem, leprosy still causes a considerable long-term morbidity in both the developing and developed world. New treatments for leprosy reactions are needed and the optimal length of multidrug therapy required further research. (AU). Descriptors: HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag HANSENIASE/terap MYCOBACTERIUM LEPRAE/imunol MYCOBACTERIUM LEPRAE/patogen QUIMIOTERAPIA COMBINADA - HANSENOSTATICOS/admin  HANSENOSTATICOS/uso terap  INFECCAO/compl  INFECCAO/etiol  SINDROME DE IMUNODEFICIÊNCIA ADQUIRIDA/compl Limits: HUMANO Location: BR191.1; 00356/s

6 / 64

HANSEN

select to print

Id: 18213 Author: Mathew, D; Kishore, B. Nanda ; Shwethadri, G. K; Sukumar; Shetty, N. J Title: An evaluation of clinical and histopathological status in paucibacillary leprosy patients after completion of sixed duration therapy ..- Source: s.l; s.n; 2004. 8 p. tab. Abstract: The presente study was carried out involving 25 patients with paucibacillary leprosy who attended the outpatient department of dermatology of Father Muller's Medical College Hospital during the period January 2001 to March 2002. All the patients were examined clinically and histopathologically at the beginning and at the end of six months of MDT and relevant data recorded. Clinicopathological correlation with histopathological classification before MDT was 72% and 68% at the end of MDT in our study. At the end of treatment 4 (16%) cases were clinically active and 8 (32%) were histopathologically active. The study showed that active cases were siginificantly reduced as a result of MDT, both clinically and histopatologically. The histopathological activity that outlasts MDT may be due to the bacillary fragments that persist; but clincial activity coupled with histopathological activity seen in 2 patients at the end of 6 months of MDT was possibly an indicator of relapse and these patients and similar others need to be follewed up for a longer duration. Is this study, resolution of granuloma and clinical activity after completion of MDT were assessed (AU). Descriptors: HANSENIASE TUBERCULOIDE/compl HANSENIASE TUBERCULOIDE/patol HANSENIASE TUBERCULOIDE/fisiopatol HANSENIASE TUBERCULOIDE/terap RESULTADO DE TRATAMENTO HANSENOSTATICOS/admin HANSENOSTATICOS/farmacol HANSENOSTATICOS/uso terap QUIMIOTERAPIA COMBINADA - HANSENIASE/clas  HANSENIASE/diag  HANSENIASE/terap Limits: HUMANO Location: BR191.1; 08999/s

7 / 64

HANSEN

select to print

Id: 18103 Author: Desforges, J. F; Thayer, W. W; Dawson, J. P Title: Hemolytic anemia induced by sulfoxone therapy, with investigations into the mechanisms of its production ?- Source: Boston; s.n; 1960. 5p p. ilus. Abstract: A case report is presented of a patient in whom clinical evidence of hemolytic anemia with methemoglobinemia developed upon increasing the dosage of sulfoxone which he was receiving for Hansen's disease. Administration of the drug was withdrawn for six weeks, after which studies were made with the use of radioactive iron to demosntrate the hemolytic effect of sulfoxone. By means of tagging cells of a single age group, it was shown that the suceptibility to hemolysis was related to cell age, and it was only after the red cells had been in the circulation for approximately fifty days that they were subject to the hemolytic effects of this drug. No significant biochemical defect could be demonstrated in the erythrocytes of this patient. However, the decline in activity of glucose-6-phosphate dehydrogenase and glutathione reductase in the aging red cell and the reported sensitivity to this drug of patients with red cell deficiency of glucose-6-phosphate dehydrogenase suggest that the hemolytic mechanism is related to this enzyme system. The case demonstrates that drug-induced hemolytic anemia of this type may occur without demonstrable enzymatic defect of the erythrocytes. The observation that patients appear to compensate for the hemolytic anemia and methemoglobinemia if maintained on this drug may be explained by the fact that the older cells containing less adequate enzyme systems are removed from the circulation and an equilibrium is maintained by increased production of red cells with a shorter age span. Descriptors: HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/sangue HANSENOSTATICOS/uso terap ANEMIA HEMOLITICA/ind quim ANEMIA HEMOLITICA/diag ANEMIA HEMOLITICA/etiol - HANSENIASE/clas  HANSENIASE/compl  HANSENIASE/diag  HANSENIASE/terap Limits: RELATO DE CASO Location: BR191.1; 00720/s

8 / 64

HANSEN

select to print

Id: 17468 Author: Trautman, J. R Title: The management of leprosy and its complications ?- Source: Louisiana; s.n; 1965. 10p p. . Descriptors: HANSENIASE/compl HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap ERITEMA NODOSO/quimioter NEURITE/quimioter NEURITE/fisiopatol AMILOIDOSE/dietoter Limits: RELATO DE CASO Location: BR191.1; 01106/d.a

9 / 64

HANSEN

select to print

Id: 17456 Author: Shepard, C. C Title: Experimental chemotherapy in leprosy ?- Source: s.l; s.n; 1976. 9p p. . Abstract: The Memorandum reviews the considerable progress that has been made in research on the chemotherapy of leprosy during the last 10-15 years, as a result of which it is now possible to study the same topics in leprosy as are studied in other bacterial diseases. Thus drugs have been screened in mice for their activity against Mycobacteerium leprae. Those that have been found to have the greatest activity against M. leprae at acceptable dosages-dapsone, rifampicin, and clofazimine-have been characterized in terms of the minimal effective dosage and rate of bacterial kill. Similarly, their pharmacokinetics in man and in certain animals have been defined. The theoretical basis for drug trials in leprosy patients is discussed in terms of the number of viable and the number of dead M.leprae that remain of various stages of therapy. Descriptors: HANSENIASE/clas HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/clas HANSENOSTATICOS/metab HANSENOSTATICOS/farmacol HANSENOSTATICOS/farmacocin QUIMIOTERAPIA COMBINADA Limits: RELATO DE CASO Location: BR191.1; 00945/s

10 / 64

HANSEN

select to print

Id: 17210 Author: S, B. B. M. Dharmendra; Chatterjee, K. R. Title: Thiosemicarbazone in the treatment of leprosy. Source: Lepr Ind;24(3):93-, july, 1952. tab. Abstract: (I) The previous work with thiosemicarbazone in the treatment of leprosy is summarised. (2) Siocarbazone brand of thiosemicarbazone has been used in 52 cases of leprosy, 9 untraeded neural cases, 27 untreated lepromatous cases and 16 previously treated lepromatous cases, 15 with sulphones, and I with hydnocarpus oil. The duration of treatment has from 2 months to 16 months with an average of I0 months. (3) The patients have stood the drug well and there has been satisfactory clinical and bacteriological response. In addition to usual therapeutic affects, special features with thiosemicarbazone treatment have been the complete or partial restoration of sensation in the anaesthetic patches and in the limbs with polyneuritic type of anaesthesia, replacement of deseased nails by new ones, and growth of new hair in depilated areas. Considering the short period of treatment those features are rather remarkable. (4) In the toxicity of thiosemicarbazone seems to be less than that of the sulphones specially in relation to its effect on the haemopoietic system. However, the thiosemicarbazone is not as free from toxicity as described by some workers eho have used it in leprosy. A special kind of toxicity which indicates specific intolerance has been noticed and this has been manifested by sudden rise of temperature even after small doses of the drug (AU). Descriptors: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/farmacol HANSENOSTATICOS/tox HANSENOSTATICOS/uso terap Location: BR191.1

11 / 64

HANSEN

select to print

Id: 17171 Author: Chatterjee, S. N. Title: Intramuscular injections of hydnocarpus oil and its preparations. Source: Lepr Ind;20(2):109-11, apr., 1948. . Descriptors: HANSENIASE HANSENOSTATICOS/admin CHAULMOOGRA/admin CHAULMOOGRA/uso terap - INJECOES INTRAMUSCULARES/instrum  INJECOES INTRAMUSCULARES/métodos Location: BR191.1

12 / 64

HANSEN

select to print

Id: 16503 Author: Tisseuil, J. Title: Injections intra-arterielles d'huile de chaulmoogra dans le traitement de la lèpre. Source: Int. J. Lepr;8(4):465-466, Oct.-Dec. 1940. . Descriptors: HANSENIASE/quimioter HANSENOSTATICOS/admin CHAULMOOGRA/admin CHAULMOOGRA/uso terap Limits: HUMANO Location: BR191.1

13 / 64

HANSEN

select to print

Id: 16079 Author: Anon. Title: American Baptist Mission leper colonies, Kengtung, Burma. Source: Lepr Ind;12(1):38-38, jan., 1940. . Descriptors: HANSENIASE/quimioter HANSENOSTATICOS/admin - MISSOES E MISSIONARIOS Location: BR191.1

14 / 64

HANSEN

select to print

Id: 15952 Author: McAuley, D. Title: Report of the leper hospital Rawalpindi for the year 1930. Source: In: Leonard Wood Memorial Conference on Leprosy.Resume of the report of the Leonard Wood Memorial Conference on Leprosy held in Manila. Manila, s.n, jan., 23 1931. p.118-120tab. Conference: Present in: Leonard Wood Memorial, Manila, jan 23, 1931. Descriptors: HANSENIASE/quimioter HANSENIASE/epidemiol HANSENOSTATICOS/admin HANSENOSTATICOS/hist - HOSPITAIS DE DERMATOLOGIA SANITARIA DE PATOLOGIA TROPICAL Location: BR191.1

15 / 64

HANSEN

select to print

Id: 15951 Author: Pency, M. C. Title: Report on the Mondalay skin clinic (leprosy) for the year ending the 31st december, 1930. Source: In: Leonard Wood Memorial Conference on Leprosy.Resume of the report of the Leonard Wood Memorial Conference on Leprosy held in Manila. Manila, s.n, jan., 23 1931. p.117-20tab. Conference: Present in: Leonard Wood Memorial, Manila, jan 23, 1931. Descriptors: HANSENIASE/quimioter HANSENIASE/epidemiol HANSENOSTATICOS/admin HOSPITAIS DE DERMATOLOGIA SANITARIA DE PATOLOGIA TROPICAL/hist Location: BR191.1

16 / 64

HANSEN

select to print

Id: 15775 Author: Christian, E. B. Title: Efficiency of institutional treatment for leprosy. Source: Lepr Ind;6(4):193-197, Oct., 1934. tab. Descriptors: HANSENIASE/quimioter ALTA DO PACIENTE/tend HANSENOSTATICOS/admin Location: BR191.1

17 / 64

HANSEN

select to print

Id: 15767 Author: Muir, E. Title: Relative painfulness of Iodised and Uniodised Esters. Source: Lepr Ind;6(3):160-161, july, 1934. . Descriptors: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/uso terap Location: BR191.1

18 / 64

HANSEN

select to print

Id: 15766 Author: Ryrie, Gordon A. Title: Statement of progress made in leprosy work in the federated Malay States in 1933. Source: Lepr Ind;6(3):150-160, july, 1934. . Descriptors: HANSENIASE/compl HANSENIASE/diag HANSENIASE/quimioter HANSENIASE/epidemiol HANSENOSTATICOS/admin HANSENIASE/cirurg Limits: HUMANO Location: BR191.1

19 / 64

HANSEN

select to print

Id: 15762 Author: Gupta, K. K. Title: An easy method of keeping hydnocarpus oil canstantly hot during injection. Source: Lepr Ind;6(3):136-136, july, 1934. ilus. Descriptors: HANSENOSTATICOS/admin HANSENOSTATICOS/uso terap CHAULMOOGRA Location: BR191.1

20 / 64

HANSEN

select to print

Id: 15751 Author: Chatterji, S. N. Title: A note on thyroid treatment in leprosy. Source: Lepr Ind;6(2):84-85, apr., 1934. tab. Descriptors: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/farmacol HANSENOSTATICOS/uso terap Limits: HUMANO Location: BR191.1

---

page 1 de 4

go to page

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information